Thromboxane is a member of the family of lipids known as eicosanoids. It is produced in platelets by thromboxane synthetase, which is produced from the endoperoxides by the cyclooxygenase (COX) enzyme from arachidonic acid. Figure 1: Basic lipid structure. ... In biochemistry, eicosanoids are a class of oxygenated hydrophobic hormones that largely function as paracrine mediators. ... A 250 ml bag of newly collected platelets. ... Cyclooxygenase (COX) is an enzyme that is responsible for formation of important biological mediators called prostanoids (including prostaglandins, prostacyclin and thromboxane). ... Arachidonic acid is a polyunsaturated fatty acid with four cis double bonds, which are the sources of its flexibility and give it the capacity to react with molecular oxygen. ...
Enzymes and substrates associated with thromoboxane and prostacyclin synthesis.
Thromboxane is a vasoconstrictor and facilitates the clumping of platelets. It is in homeostatic balance in the circulatory system with prostacyclin, a related compound. The widely-used drug aspirin acts by inhibiting the ability of the COX enzyme to synthesize the precursors of thromboxane within platelets. A vasoconstrictor is any substance that acts to constrict blood vessels, i. ... Homeostasis or homoeostasis is the property of an open system, especially living organisms, to regulate its internal environment so as to maintain a stable condition, by means of multiple dynamic equilibrium adjustments controlled by interrelated regulation mechanisms. ... The circulatory system or cardiovascular system is the organ system which circulates blood around the body of most animals. ... Prostacyclin is a member of the family of lipid molecules known as eicosanoids. ... http://www. ...
Thromboxane is named for its role in clot formation (thrombosis). Thrombosis is the formation of a clot or thrombus inside a blood vessel, obstructing the flow of blood through the circulatory system. ...
We therefore compared the excretion of a thromboxane metabolite and platelet function in 50 patients with Type II diabetes mellitus who had normal renal function and clinical evidence of macrovascular disease and in 32 healthy controls.
The fractional conversion of exogenous thromboxaneB2 (infused at a rate of 4.5, 45.3, or 226.4 fmol per kilogram of body weight per second) to urinary 11-dehydro-thromboxane B2 was assessed in four patients, in whom it averaged 5.4 +/- 0.1 percent; this value did not differ from that measured in healthy subjects.
Picotamide, a combined inhibitor of thromboxaneA2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study.
Thromboxane: A substance made by platelets that causes blood clotting and constriction of blood vessels.
Thromboxane A2 (TXA2) is active but is very unstable and has a half-life of only 30 seconds before it undergoes hydrolysis to form thromboxane B2 (TXB2) which is inactive.
Feeds |
Contact